Literature DB >> 8646410

Inhibition of vagally mediated gastric acid secretion by activation of central prostanoid EP3 receptors in urethane-anaesthetized rats.

K Yokotani1, Y Okuma, Y Osumi.   

Abstract

1. We studied the effects of intracerebroventricular (i.c.v.) administration of prostanoid EP receptor ligands on vagally stimulated gastric acid secretion in rats anaesthetized with urethane. 2. Administration of misoprostol (EP3/EP2 receptor agonist) and sulprostone (EP3/EP1 receptor agonist) reduced vagally mediated gastric acid secretion in a dose-dependent manner (0.1, 0.3 and 1.0 nmol per animal). Butaprost (EP2 receptor agonist) (0.3 and 3.0 nmol per animal) was without effect. 17-Phenyl-omega- trinor PGE2 (EP1/EP3 receptor agonist) attenuated vagally mediated gastric acid secretion only at its highest dose (1.0 nmol per animal); this antisecretory effect was not prevented by pretreatment with SC-19220 (selective EP1 receptor antagonist) (20 nmol per animal, i.c.v.). 3. The potency of these test agents in attenuation of vagally mediated gastric acid secretion was as follows: misoprostol > or = sulprostone > > 17-phenyl-omega-trinor PGE2 > > > butaprost. These results suggest that activation of central prostanoid EP3 receptors induces inhibition of vagally mediated gastric acid secretion in rats.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8646410      PMCID： PMC1909351          DOI： 10.1111/j.1476-5381.1996.tb15240.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  26 in total

Review 1.  Prostaglandins in hypothalamo-pituitary and ovarian function.

Authors:  H R Behrman
Journal:  Annu Rev Physiol       Date:  1979       Impact factor: 19.318

2.  Hypothalamic integration: organization of the paraventricular and supraoptic nuclei.

Authors:  L W Swanson; P E Sawchenko
Journal:  Annu Rev Neurosci       Date:  1983       Impact factor: 12.449

3.  Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system.

Authors:  Y Sugimoto; R Shigemoto; T Namba; M Negishi; N Mizuno; S Narumiya; A Ichikawa
Journal:  Neuroscience       Date:  1994-10       Impact factor: 3.590

4.  Antagonism of prostaglandin E2 by 1-acetyl-2-(8-chloro-10,11-dihydrodibenz (b,f) (1,4) oxazepine-10-carbonyl) hydrazine (SC-19220).

Authors:  J H Sanner
Journal:  Arch Int Pharmacodyn Ther       Date:  1969-07

5.  The effect of sympathetic nerve stimulation on serum gastrin, gastric acid secretion and mucosal blood flow responses to meat extract stimulation in anaesthetized cats.

Authors:  E L Blair; E R Grund; J D Reed; D J Sanders; G Sanger; B Shaw
Journal:  J Physiol       Date:  1975-12       Impact factor: 5.182

6.  Central and peripheral antialgesic action of aspirin-like drugs.

Authors:  S H Ferreira; B B Lorenzetti; F M Corrêa
Journal:  Eur J Pharmacol       Date:  1978-12-15       Impact factor: 4.432

7.  Prostacyclin-induced hyperthermia: implication of a protein mediator.

Authors:  S B Kandasamy; B A Williams
Journal:  Neuropharmacology       Date:  1982-10       Impact factor: 5.250

Review 8.  Eicosanoids: prostaglandins, thromboxanes, leukotrienes, and other derivatives of carbon-20 unsaturated fatty acids.

Authors:  L S Wolfe
Journal:  J Neurochem       Date:  1982-01       Impact factor: 5.372

9.  Studies on the characterisation of prostanoid receptors: a proposed classification.

Authors:  I Kennedy; R A Coleman; P P Humphrey; G P Levy; P Lumley
Journal:  Prostaglandins       Date:  1982-11

10.  Prejunctional prostanoid receptors on cardiac adrenergic terminals belong to the EP3 subtype.

Authors:  L Mantelli; S Amerini; A Rubino; F Ledda
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739
View more
  4 in total

1.  Genetic deletion of the prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical and functional outcomes after intracerebral hemorrhage.

Authors:  Jenna L Leclerc; Andrew S Lampert; Matthew A Diller; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2015-05       Impact factor: 3.386

2.  Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.

Authors:  L Walch; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors.

Authors:  Tomonori Kunikata; Akiko Tanaka; Tohru Miyazawa; Shinichi Kato; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

4.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.